Prediction models of long‐term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles

Mei‐Hsuan Lee, Hwai‐I. Yang, Jessica Liu, Richard Batrla‐Utermann, Chin‐Lan Jen, Uchenna H. Iloeje, Sheng‐Nan Lu, San‐Lin You, Li‐Yu Wang, Chien‐Jen Chen, R.E.V.E.A.L.‐HBV Study Group – 15 March 2013 – Integrating host and HBV characteristics, this study aimed to develop models for predicting long‐term cirrhosis and hepatocellular carcinoma (HCC) risk in chronic hepatitis B virus (HBV) patients.

Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta‐analysis

Sarah Larney, Hannah Kopinski, Curt G. Beckwith, Nickolas D. Zaller, Don Des Jarlais, Holly Hagan, Josiah D. Rich, Brenda J. Bergh, Louisa Degenhardt – 15 March 2013 – People detained in prisons and other closed settings are at elevated risk of infection with hepatitis C virus (HCV). We undertook a systematic review and meta‐analysis with the aim of determining the rate of incident HCV infection and the prevalence of anti‐HCV among detainees in closed settings. We systematically searched databases of peer‐reviewed literature and widely distributed a call for unpublished data.

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Mark S. Sulkowski, Marc Bourlière, Jean‐Pierre Bronowicki, Tarik Asselah, Jean‐Michel Pawlotsky, Stephen D. Shafran, Stanislas Pol, Stefan Mauss, Dominique Larrey, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher – 15 March 2013 – Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor.

Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra‐deep pyrosequencing

Christophe Rodriguez, Stéphane Chevaliez, Paul Bensadoun, Jean‐Michel Pawlotsky – 15 March 2013 – Hepatitis B virus (HBV) resistance to nucleoside/nucleotide analogs is frequent. Ultra‐deep pyrosequencing (UDPS) is a powerful new tool that can detect minor viral variants and characterize complex quasispecies mixtures. We used UDPS to analyze the dynamics of adefovir‐resistant HBV variants in patients with chronic HBV infection in whom adefovir resistance occurred during treatment. Amino acid substitutions known to confer resistance to adefovir were detected at baseline in most patients.

Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta‐analysis

Sarah Larney, Hannah Kopinski, Curt G. Beckwith, Nickolas D. Zaller, Don Des Jarlais, Holly Hagan, Josiah D. Rich, Brenda J. Bergh, Louisa Degenhardt – 15 March 2013 – People detained in prisons and other closed settings are at elevated risk of infection with hepatitis C virus (HCV). We undertook a systematic review and meta‐analysis with the aim of determining the rate of incident HCV infection and the prevalence of anti‐HCV among detainees in closed settings. We systematically searched databases of peer‐reviewed literature and widely distributed a call for unpublished data.

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

Fiona McPhee, Dennis Hernandez, Fei Yu, Joseph Ueland, Aaron Monikowski, Arlene Carifa, Paul Falk, Chunfu Wang, Robert Fridell, Timothy Eley, Nannan Zhou, David Gardiner – 15 March 2013 – In a sentinel cohort, hepatitis C virus (HCV) patients (primarily genotype [GT] 1a) were treated with daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor). Preexistence, emergence, and persistence of resistance variants in patients who failed this treatment are described.

Platelet‐derived growth factor‐D and Rho GTPases regulate recruitment of cancer‐associated fibroblasts in cholangiocarcinoma

Massimiliano Cadamuro, Giorgia Nardo, Stefano Indraccolo, Luigi Dall'Olmo, Luisa Sambado, Lidia Moserle, Irene Franceschet, Michele Colledan, Marco Massani, Tommaso Stecca, Nicolò Bassi, Stuart Morton, Carlo Spirli, Romina Fiorotto, Luca Fabris, Mario Strazzabosco – 15 March 2013 – Cholangiocarcinoma (CCA) is characterized by an abundant stromal reaction. Cancer‐associated fibroblasts (CAFs) are pivotal in tumor growth and invasiveness and represent a potential therapeutic target.

Subscribe to